BRAF mutant PD-L1 positive metastatic musculoskeletal lesions from primary lung adenocarcinoma treated with combination vemurafenib and pembrolizumab: a case report.
Humans
Male
Antibodies, Monoclonal, Humanized
/ therapeutic use
Middle Aged
Proto-Oncogene Proteins B-raf
/ genetics
Lung Neoplasms
/ drug therapy
Vemurafenib
/ therapeutic use
Adenocarcinoma of Lung
/ drug therapy
B7-H1 Antigen
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Mutation
Immune Checkpoint Inhibitors
/ therapeutic use
BRAFmu
Musculoskeletal metastasis
NSCLC
PDL-1 overexpression
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
07
06
2023
accepted:
15
08
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
B-Raf mutation positivity, B-Raf mutation positivity occurrence with programmed death ligand 1 overexpression, and musculoskeletal metastasis are singly rare in non-small cell lung cancer, and even rarer is all occurring in one patient. A Filipino 63-year-old male had B-Raf mutation positive and programmed death ligand 1 overexpressed symptomatic metastatic musculoskeletal lesions from lung adenocarcinoma treated with a BRAF inhibitor, vemurafenib, in combination with an immune checkpoint inhibitor, pembrolizumab. He exhibited significant reduction in pain and burden of musculoskeletal metastatic lesions. Although a rare occurrence and known to have a poor prognosis, B-Raf mutation positive programmed death ligand 1 overexpressed lung adenocarcinoma presenting with metastatic musculoskeletal lesions can respond favorably to a combination immune checkpoint inhibitor and BRAF inhibitor medication.
Sections du résumé
BACKGROUND
BACKGROUND
B-Raf mutation positivity, B-Raf mutation positivity occurrence with programmed death ligand 1 overexpression, and musculoskeletal metastasis are singly rare in non-small cell lung cancer, and even rarer is all occurring in one patient.
CASE PRESENTATION
METHODS
A Filipino 63-year-old male had B-Raf mutation positive and programmed death ligand 1 overexpressed symptomatic metastatic musculoskeletal lesions from lung adenocarcinoma treated with a BRAF inhibitor, vemurafenib, in combination with an immune checkpoint inhibitor, pembrolizumab. He exhibited significant reduction in pain and burden of musculoskeletal metastatic lesions.
CONCLUSION
CONCLUSIONS
Although a rare occurrence and known to have a poor prognosis, B-Raf mutation positive programmed death ligand 1 overexpressed lung adenocarcinoma presenting with metastatic musculoskeletal lesions can respond favorably to a combination immune checkpoint inhibitor and BRAF inhibitor medication.
Identifiants
pubmed: 39334445
doi: 10.1186/s13256-024-04773-z
pii: 10.1186/s13256-024-04773-z
doi:
Substances chimiques
pembrolizumab
DPT0O3T46P
Antibodies, Monoclonal, Humanized
0
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Vemurafenib
207SMY3FQT
B7-H1 Antigen
0
BRAF protein, human
EC 2.7.11.1
CD274 protein, human
0
Immune Checkpoint Inhibitors
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
450Informations de copyright
© 2024. The Author(s).
Références
Baik C, Myall N, Wakelee H. Targeting BRAF-mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy. Oncologist. 2017;22:1–11.
doi: 10.1634/theoncologist.2016-0458
Stinchcombe T. Targeted therapies for lung cancer. Lung Cancer, Cancer Treat Res. 2016;170:165–82.
doi: 10.1007/978-3-319-40389-2_8
pubmed: 27535394
Sachez-Torres J, Viteri S, Molina M, Rosell R. BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. Transl Lung Cancer Res. 2013;2(3):244–50.
Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel-Plucinska N, Crzegrzolka J, Podhorska-Okolow M, Dziegel P, Nowinska K. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci. 2019;20(824):1–15.
Pandey R, Shukla S, Husain N, Islam MH, Hadi R, Tripathi KS, Singhal A. Correlation between programmed death ligand-1 (PD-L1) expression and driver gene mutations in non-small cell lung carcinoma- adenocarcinoma phenotype. Asian Pac J Cancer Prev. 2021;23(1):131–42.
doi: 10.31557/APJCP.2022.23.1.131
Li C, Liu K, Xie Z, Zhu F, Cheng B, Liang H, Li J, Xiong S, Chen Z, Liu Z, Zhao Y, Ou L, Zhong R, Wang W, Huang J, Sun J, Zhang C, Weng L, He J, Liang W, Pan Z. PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China. Therapeut Adv Med Oncol. 2020;12:1–10.
Dudnik E, Bshara E, Grubstein A, Fridel L, Shocat T, Roisman LC, Ilouze M, Rozenblum AB, Geva S, Zer A, Rotem O, Allen AM, Peled N. Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): outcomes with immune check-point inhibitors (ICPi). Lung Cancer. 2018;124:117–24.
doi: 10.1016/j.lungcan.2018.07.044
pubmed: 30268448
Dudnik E, Peled N, Nechushtan H, Wollner M, Onn A, Agbarya A, Moskovitz M, Keren S, Popovits-Hadari N, Urban D, Mishaeli M, Zer A, Allen AM, Rabinovich NM, Rotem O, Kuznetsov T, Shochat T, Toisman LC, Bar J. BRAF mutant lung cancer: PD-L1 expression, tumor mutational burden, microsatellite instability status and response to immune check-point inhibitors. J Thoracic Oncol. 2018;13(8):1128–37.
doi: 10.1016/j.jtho.2018.04.024
Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Fruh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild DI, Bironzao P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gaurschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019. https://doi.org/10.1093/annonc/mdz167 .
doi: 10.1093/annonc/mdz167
pubmed: 31584608
Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, Tiseo M, Planchard D. BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat Rev Cancer Treat Rev. 2018. https://doi.org/10.1016/j.ctrv.2018.04.006 .
doi: 10.1016/j.ctrv.2018.04.006
pubmed: 29729495
O’Leary C, Andelkovic V, Ladwa R, Pavlakis N, Zhou C, Hirsch F, Richard D, O’Byrne K. Targeting BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res. 2019;8(6):1119–24.
doi: 10.21037/tlcr.2019.10.22
pubmed: 32010589
Cui G, Liu D, Li W, Fu X, Liang Y, Li Y, Shi W, Chen X, Zhao S. A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer. Medicine. 2017;96: e6552.
doi: 10.1097/MD.0000000000006552
pubmed: 28383426
Marchetti A, Felicioni L, Malatesta S, Sciarrotta MG, Guetti L, Chella A, Viola P, Pullara C, Mucilli F, Buttitta F. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574–9.
doi: 10.1200/JCO.2011.35.9638
pubmed: 21825258
Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Janne PA. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19:4532–40.
doi: 10.1158/1078-0432.CCR-13-0657
pubmed: 23833300
Zou W, Wolchok JD, Chen L. PD-L1 (B7–H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016. https://doi.org/10.1126/scitranslmed.aad7118 .
doi: 10.1126/scitranslmed.aad7118
pubmed: 27903862
Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S, Mitchell P, Boutros P, John T. PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected NSCLC. PLoS ONE. 2016;11: e0153954.
doi: 10.1371/journal.pone.0153954
pubmed: 27104612
Dantoing E, Piton N, Salaun M, et al. Anti-PD1/PD-L1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations. Int J Mol Sci. 2021;22(6288):1–13.
Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenergre A, Robinet G, Auliac JB, Gervais R, Chouaid C. Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer. Target Oncol. 2017;12:563–9.
doi: 10.1007/s11523-017-0510-9
pubmed: 28624922
Pelster M, Amaria R. Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Therapeut Adv Med Oncol. 2019;11:1–11.
Lopez-Gonzalez A, Huelves M, Garcia AL, Provencio M. Skeletal muscle metastasis from NSCL. J Thorac Dis. 2012;4(2):232–4.
pubmed: 22833837
Lozi AA, Silconi ZB, Misljenovi N. Metastases to rare locations as the initial manifestation of non-small cell lung cancer: two case reports. Coll Antropol. 2010;34:609–12.
Pop D, Nadeemy AS, Venissac N, Guiraudet P, Otto J, Poudenx M, Mouroux J. Skeletal muscle metastasis from non-small cell lung cancer. J Thorac Oncol. 2009;4:1236–41.
doi: 10.1097/JTO.0b013e3181b24509
pubmed: 19641472
Sridhar KS, Rao RK, Kunhardt B. Skeletal muscle metastases from lung cancer. Cancer. 1987;59:1530–4.
doi: 10.1002/1097-0142(19870415)59:8<1530::AID-CNCR2820590824>3.0.CO;2-H
pubmed: 2434211
Ryan A, Chlabra R, Hughes A. Muscular metastasis, a rare presentation of non-small-cell lung cancer. MedGenMed. 2007;9:20.
Weiss L. Biomechanical destruction of cancer cells in skeletal muscle: a rat-regulator for hematogenous metastasis. Clin Exp Metastasis. 1989;7:483–91.
doi: 10.1007/BF01753809
pubmed: 2752602
Seely S. Possible reasons for the high resistance of muscle to cancer. Med Hypotheses. 1980;6:133–7.
doi: 10.1016/0306-9877(80)90079-1
pubmed: 7393016
Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. PLoS ONE. 2015;10: e0131403.
doi: 10.1371/journal.pone.0131403
pubmed: 26114883